Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31011728 | 1.00 | CYP19A1 (0.49) | CYP19A1MAPTHPGDIDO1ALOX15 | |
| SCHEMBL319801 | 0.83 | CYP19A1 (0.51) | CYP19A1MAPTHPGDIDO1ALOX15 | |
| SCHEMBL3627132 | 0.82 | KDM1A (0.48) | CYP19A1MAPTIDO1MEN1KMT2A | |
| SCHEMBL3624500 | 0.78 | AGPAT2 (0.42) | MAPTHPGDMEN1KMT2AUSP2 | |
| SCHEMBL31011561 | 0.78 | AGPAT2 (0.42) | MAPTHPGDMEN1KMT2AUSP2 | |
| SCHEMBL445044 | 0.77 | KMO (0.47) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL3626348 | 0.77 | TOP2A (0.41) | MEN1KMT2AKDM4ECDK1CDK2 | |
| SCHEMBL31011607 | 0.77 | ALDH1A1 (0.38) | CYP19A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL31011602 | 0.76 | CYP19A1 (0.45) | CYP19A1MAPTHPGDIDO1ALOX15 | |
| SCHEMBL3626006 | 0.76 | CYP19A1 (0.45) | CYP19A1MAPTHPGDIDO1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661966-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | Type6 Therapeutics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024167848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | TYPE6 THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-9353090-B2 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-31 | — | — | US | disclosed |
| US-9353090-B2 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-31 | — | — | US | disclosed |
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2016014463-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2010015653-A1 | PYRIMIDINE DERIVATIVES AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015653-A1 | PYRIMIDINE DERIVATIVES AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ADCY9, ADCY7, GUCY1B1 | CYP19A1 1230/4885MAPT 4642/4885HPGD 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.